GenBody COVID-19 Ag

Detection of SARS-CoV-2 Antigen

GenBody-COVID

Contact Us For Customized Pricing and Expert Support

For Emergency Use Authorization (EUA) Only*  |  For In Vitro Diagnostic Use  |  For Prescription Use Only

Why Choose GenBody Ag Test:

HIGHLY ACCURATE: Identifies acute SARS-COV-2 infection with high accuracy

RAPID DETECTION: Delivers accurate results in only 15 minutes

SIMPLE TO USE: Simple 5-step procedure Minimal training required

PATIENT FRIENDLY: Painless shallow nasal swab sample collection available

CONTROLS INCLUDED: Internal built-in control &
external controls provided 

Product Specifications

 

INTENDED USE: for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct nasopharyngeal (NP) or anterior nasal (AN) swab specimens. Please see the Instructions for Use for the full intended use.

 

ACCURACY: Sensitivity: 92.31%, Specificity: 99.04%

 

CPT CODE: 87811-QW

 

SHELF LIFE: 21 months

 

STORAGE CONDITIONS: 2-30°C/36-86°F

Test Procedure

qrg

Ordering Information

Product: WELLlife™ COVID-19 / Influenza A&B Test

Configuration: 25 tests per kit

Verséa SKU#: GB-COVAG025-NU-1

* The GenBody COVID-19 Ag has not been FDA cleared or approved, but has been authorized by FDA under an Emergency Use Authorization for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate, high or waived complexity tests. This product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.